LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company today announced the launch of the Abraxis Patient Access Program (APAP), a comprehensive patient assistance program for cancer patients being treated with ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). Through APAP, financially eligible cancer patients in need of treatment with ABRAXANE will receive access to the drug at no cost. This new program, which replaces the previous ABRAXANE patient assistance programs, makes it possible for financially eligible cancer patients to receive assistance in all instances where ABRAXANE has been prescribed.
